Clinical Studies
n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study

https://doi.org/10.1016/S0735-1097(99)00054-6Get rights and content
Under an Elsevier user license
open archive

Abstract

OBJECTIVES

The aim of the study was to investigate whether omega-3 fatty acids (n-3 FA) reduce the occurrence of restenosis after percutaneous transluminal coronary angioplasty.

BACKGROUND

Meta-analyses have shown significant reduction of restenosis after coronary angioplasty upon supplementation with n-3 FA.

METHODS

In a prospective, placebo-controlled, double-blind study, 500 patients were randomly allocated to treatment with n-3 FA (Omacor™, Pronova AS, Oslo, Norway) 5.1 g/day or corn oil (placebo) starting at least two weeks prior to elective coronary angioplasty. The treatment was continued until restenosis evaluation by quantitative coronary angiography after six months. Stenosis was defined as a minimal luminal diameter (MLD) <40% of the reference diameter. Successful coronary angioplasty was defined as ≥20% acute gain in MLD and a residual stenosis <50%. Restenosis was defined as ≥20% late loss of diameter and stenosis >50% or an increase in stenosis of ≥0.7 mm. Three-hundred ninety-two patients fulfilled the criteria for initial stenosis and successful coronary angioplasty, and, except four patients who died, none were lost for follow-up.

RESULTS

Restenosis occurred in 108/266 (40.6%) of the treated stenoses in the Omacor group and in 93/263 (35.4%) in the placebo group (odds ratio [OR] 1.25, 95% confidence interval [CI] [0.87–1.80] p = 0.21). In the Omacor group one or more restenoses occurred in 90/196 (45.9%) patients as compared with 86/192 (44.8%) in the placebo group (OR 1.05, 95% CI [0.69–1.59] p = 0.82).

CONCLUSIONS

Supplementation with 5.1 g n-3 FA/day for six months, initiated at least two weeks prior to coronary angioplasty did not reduce the incidence of restenosis.

Abbreviations

CI
confidence interval
CART
Coronary Angioplasty Restenosis Trial
DHA
docosahexaenoic acid
EPA
eicosapentaenoic acid
EMPAR
Enoxaparin MaxEPA Prevention of Angioplasty Restenosis
MLD
minimal luminal diameter
NYHA
New York Heart Association
OR
odds ratio
n-3 FA
omega-3 fatty acids

Cited by (0)

This study was supported in part by a research grant from Pronova AS Oslo, Norway.